Showing 61 - 80 results of 47,018 for search '(( 5 non decrease ) OR ((( 5 ((ng decrease) OR (we decrease)) ) OR ( 50 a decrease ))))', query time: 1.00s Refine Results
  1. 61
  2. 62
  3. 63
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69
  10. 70
  11. 71
  12. 72
  13. 73
  14. 74
  15. 75
  16. 76

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  17. 77
  18. 78
  19. 79
  20. 80